Should you buy Privia Health Group (PRVA)?
Updated
Privia Health Group is growing revenue at 26% annually with strong analyst conviction (8.9/10 rating, 36% upside target) and exceptional free cash flow conversion of 508%, but a quality score of 3.5 below the minimum threshold and the recent Q1 2026 earnings miss are key risks to monitor.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Privia Health grew revenue by 26% year over year and the business achieved a Piotroski F-Score of 7/9, reflecting broad improvement across profitability, leverage, and operational efficiency metrics for this healthcare IT platform. Growth breakdown | Annual revenue growth remains above 15% in the next reported fiscal year, demonstrating that the physician enablement platform continues to scale at above-average industry rates. | →Stable |
| CounterHealthcare IT platform revenue growth can be lumpy depending on provider network onboarding timing, and 26% may front-load benefits that slow in the following year. | ||
Free cash flow is 508% of reported net income, indicating that accounting earnings significantly understate actual cash generation, and this gap likely reflects amortization of acquired intangibles that suppress GAAP net income without representing economic cost. Quality breakdown | Free cash flow conversion remains above 200% of net income in the next annual period, confirming the structural cash generation advantage. | →Stable |
| CounterFCF-to-net-income ratios this high often normalize as intangible amortization tails off or as growth capex ramps, making the premium relative to GAAP earnings temporary. | ||
Analysts rate Privia at 8.9 out of 10 and see 36% upside to a consensus target, with the current analyst target implying a price of $28.28 versus the current $23.02, making this one of the higher analyst conviction setups in the healthcare information services group. Sentiment | Analyst price target is maintained or raised and price appreciates toward $28 within 12 months, capturing at least half of the implied analyst upside. | →Stable |
| CounterHigh analyst ratings and upside estimates in healthcare IT have frequently been disappointed by reimbursement pressure, regulatory changes, or slower-than-expected physician adoption. | ||
Privia Health grew revenue by 26% year over year and the business achieved a Piotroski F-Score of 7/9, reflecting broad improvement across profitability, leverage, and operational efficiency metrics for this healthcare IT platform.
→Stable- Expectation
- Annual revenue growth remains above 15% in the next reported fiscal year, demonstrating that the physician enablement platform continues to scale at above-average industry rates.
CounterHealthcare IT platform revenue growth can be lumpy depending on provider network onboarding timing, and 26% may front-load benefits that slow in the following year.
Free cash flow is 508% of reported net income, indicating that accounting earnings significantly understate actual cash generation, and this gap likely reflects amortization of acquired intangibles that suppress GAAP net income without representing economic cost.
→Stable- Expectation
- Free cash flow conversion remains above 200% of net income in the next annual period, confirming the structural cash generation advantage.
CounterFCF-to-net-income ratios this high often normalize as intangible amortization tails off or as growth capex ramps, making the premium relative to GAAP earnings temporary.
Analysts rate Privia at 8.9 out of 10 and see 36% upside to a consensus target, with the current analyst target implying a price of $28.28 versus the current $23.02, making this one of the higher analyst conviction setups in the healthcare information services group.
→Stable- Expectation
- Analyst price target is maintained or raised and price appreciates toward $28 within 12 months, capturing at least half of the implied analyst upside.
CounterHigh analyst ratings and upside estimates in healthcare IT have frequently been disappointed by reimbursement pressure, regulatory changes, or slower-than-expected physician adoption.
▸ Show 1 more pillar▾ Show fewer
The quality score of 3.5 falls below the minimum 4.0 threshold, and the most recent quarter ended May 2026 showed a -24% earnings miss, introducing uncertainty about whether the strong historical beat record (3 of 4 quarters) can be maintained.
→Stable- Expectation
- The next quarterly earnings report delivers a positive surprise above 10%, and quality metrics improve to above 4.0 within 2 reporting cycles.
CounterA single miss in an otherwise strong beat track record could be noise, especially if the Q1 miss was driven by a one-time cost item rather than structural deterioration.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Privia Health grew revenue by 26% year over year and the business achieved a Piotroski F-Score of 7/9, reflecting broad improvement across profitability, leverage, and operational efficiency metrics for this healthcare IT platform.
Trip ifAnnual revenue growth falls below 10% in the next reported fiscal year.
- P2Free cash flow is 508% of reported net income, indicating that accounting earnings significantly understate actual cash generation, and this gap likely reflects amortization of acquired intangibles that suppress GAAP net income without representing economic cost.
Trip ifFree cash flow conversion drops below 100% of net income in any reported annual period.
- P3Analysts rate Privia at 8.9 out of 10 and see 36% upside to a consensus target, with the current analyst target implying a price of $28.28 versus the current $23.02, making this one of the higher analyst conviction setups in the healthcare information services group.
Trip ifAnalyst consensus price target falls below $22, reducing implied upside to less than 5% from current levels.
- P4The quality score of 3.5 falls below the minimum 4.0 threshold, and the most recent quarter ended May 2026 showed a -24% earnings miss, introducing uncertainty about whether the strong historical beat record (3 of 4 quarters) can be maintained.
Trip ifEarnings miss rate rises to 3 or more misses in the next 4 quarters, with average negative surprise below -15%.
How the engine reached this verdict
TrendMatrix's engine output for Privia Health Group, Inc. (PRVA) is SELL_IF_HOLDING with medium conviction, score 6.0/10 at $24.50. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold. Co-failing gates ( ASYMMETRY:1.0<1.5@spot) reinforce the read; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The dominant failed gate is reward-to-risk at 1.0 vs threshold 1.5. SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.6>=5.5.
On the bear side: Quality below floor (3.5 < 4.0). Active engine warnings: Quality below floor (3.5 < 4.0), V9 Gate Failed: ASYMMETRY:1.0<1.5@spot.
The engine's exit framework anchors to a tactical sell band near $24.50, with structural invalidation at $23.32. The asymmetric R:R against a reversal hypothesis is 3.14 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates PRVA — 10-dimension breakdown →
Bear case
- ▸Quality below floor (3.5 < 4.0)